

ORAL PRESENTATION

Open Access

Update of the quality assurance (QA) results of halothane and caffeine analysis of all current participating malignant hyperthermia units

Nickla Fisher*, Helena Wright, Philip Hopkins

From 33rd Annual Meeting of the European Malignant Hyperthermia Group (EMHG)
Würzburg, Germany. 15-17 May 2014

Background

The provision of a Quality Assurance Scheme for members of the European Malignant Hyperthermia Group (EMHG) is to ensure that the concentrations of halothane and caffeine in the tissue bath are as stipulated in the in vitro contracture test (IVCT) protocol. Confirmation of the correct concentrations in the tissue bath is an essential part of the IVCT protocol.

The focus of this presentation will be to provide an update of the QA results from the analysis of both halothane and caffeine from all of the participating units over a period of three years.

The aims are to show

1. How many malignant hyperthermia (MH) units have achieved the target concentrations of halothane for nominal vaporiser settings of 0.5% (0.11mM) and 2.0% (0.44mM) and caffeine concentrations of 0.5mM and 2.0mM?
2. How these halothane concentrations can vary within each lab?

Results

Each lab is aware of its own results. Anonymised results from January 2012 to January 2014 will be presented from each participating MH unit.

These will include halothane results for vaporiser settings of 0.5% and 2.0%. The tissue bath concentration is usually lower than the required concentration, but halothane concentrations can also be found to be higher. Halothane concentrations can also vary within each lab.

Caffeine analysis results collected over the past 24 months will also be presented from each participating lab.

Published: 18 August 2014

doi:10.1186/1471-2253-14-S1-A5

Cite this article as: Fisher et al.: Update of the quality assurance (QA) results of halothane and caffeine analysis of all current participating malignant hyperthermia units. *BMC Anesthesiology* 2014 **14**(Suppl 1):A5.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

 **BioMed Central**

Leeds Institute of Molecular Medicine, St James's University Hospital, LS9 7TF
Leeds, UK

 **BioMed Central**

© 2014 Fisher et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.